SCHEDULE: MAK Capital Discloses 5.8% Stake in Protalix BioTherapeutics

MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have jointly reported a 5.8% beneficial ownership stake in Protalix BioTherapeutics, Inc.

Summary

• MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons beneficially own 4,649,599 shares of Protalix BioTherapeutics, Inc. Common Stock.
• This ownership represents 5.8% of the total outstanding Common Stock.
• The calculation is based on 80,421,181 total shares outstanding as of November 1, 2025, as reported by Protalix BioTherapeutics in its Form 10-Q filed November 13, 2025.
• The Reporting Persons have shared voting power and shared dispositive power over all 4,649,599 shares.
• The shares were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mildly positive development. The disclosure of a new significant passive stake by an institutional investor suggests a vote of confidence in Protalix BioTherapeutics, though it does not provide new operational or financial insights.

Positives

• Increased institutional ownership by MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman, signaling potential confidence in Protalix BioTherapeutics.
• The acquisition is stated to be for passive investment purposes, not for changing or influencing control, which can reduce uncertainty regarding potential activist interventions.

Industry Context

StockSavvy.ai notes that an increase in institutional ownership, particularly a new 5.8% stake by an investment fund, can often be interpreted as a positive signal within the biotechnology sector, indicating that sophisticated investors see value or potential in the company's pipeline or market position. This type of passive investment suggests a belief in the company's current trajectory without an intent to influence management or strategy.

Comparison to Industry Standards

• A 5.8% beneficial ownership stake is a significant position for an institutional investor in a publicly traded company, often placing the holder among the top shareholders.
• While this filing does not provide specific financial or operational results for direct comparison, such a stake typically signals a level of confidence in the company's long-term prospects, aligning with common institutional investment strategies in the biotech space where long development cycles and regulatory hurdles are prevalent.

Stakeholder Impact

• Shareholders: May view the new institutional ownership as a positive indicator of investor confidence, potentially leading to increased interest and stability in the stock.
• Management: The passive nature of the stake (not for control) suggests that current management and strategy are not immediately challenged by this new ownership.

Key Dates

Recommendation

A seasoned investor would likely recommend a 'hold' based solely on this Schedule 13G filing. While the disclosure of a new 5.8% passive stake by an institutional investor is a positive signal of confidence, this filing does not provide sufficient fundamental financial or operational data to warrant a 'buy' or 'sell' recommendation. It indicates institutional interest but does not change the underlying investment thesis without further analysis of the company's performance and outlook.

Keywords

Protalix BioTherapeutics, PLX, MAK Capital Fund, MAK Capital One, Michael A. Kaufman, Beneficial Ownership, Schedule 13G, Institutional Investment, Biotechnology, Common Stock